Urine test tracks tissue senescence after injection
Measuring tissue aging usually requires a biopsy or imaging scan. A newly developed probe could make it as simple as collecting urine after a single injection.
Researchers at Nature Aging describe an albumin-based nanoprobe (a small particle built from a protein naturally found in blood). The probe is engineered to respond to an enzyme called MMP-7, which is more active in aged or scarred tissue. When MMP-7 cleaves the probe, a signal molecule is released, filtered by the kidneys, and excreted in urine.
The study tested the approach in lung cancer and pulmonary fibrosis (scar tissue in the lungs), two conditions where cellular aging plays a central role. The probe detected the presence of senescent cells and tracked whether treatment was having an effect.
Why measuring senescence is hard
Senescent cells are cells that have stopped dividing but do not die. They release signaling molecules that can damage surrounding tissue. In small amounts they aid wound healing. When they accumulate, they contribute to aging and disease.
Measuring that accumulation has been difficult. Blood tests give an incomplete picture. Tissue sampling is invasive. A urine-based approach could change that: non-invasive, repeatable, and sensitive enough to track treatment response over time.
Not ready for clinical use yet
The study was conducted in mice and cell models. Translating the method to humans will require extensive testing for safety and reliability. The injection step also needs optimization before it can be broadly applied.
Even so, the direction is significant. One of the biggest gaps in anti-aging medicine is objective measurement. If a treatment reduces cellular senescence, there is currently no easy way to confirm that. A urine readout could become a practical monitoring tool for future longevity therapies.